Skip to content
iMedicines
  • Find a medicine
  • Patients support program
  • Follow Us
  • Linkedin
  • YouTube
  • About Us
  • Patients
  • Products
  • Careers
  • Stay & read
  • Contact Us
  • Eng
  • Por
  • Esp
Insights & Highlights Medical News Pharma Industry Insights Public Health
Rare Disease Research in Latin America: A Landscape of Promise and Potential
16 de January de 2025 | Pharma Industry Insights

Rare Disease Research in Latin America: A Landscape of Promise and Potential

Innovative Medicines Annual Meeting (IMAM) 2024
3 de January de 2025 | Insights & Highlights

Innovative Medicines Annual Meeting (IMAM) 2024

SLEIMPN 2024: A Gathering of Learning and Impact
3 de January de 2025 | Insights & Highlights

SLEIMPN 2024: A Gathering of Learning and Impact

Enzyme Replacement Therapy Shows Long-Term Promise for Alpha-Mannosidosis
3 de December de 2024 | Medical News

Enzyme Replacement Therapy Shows Long-Term Promise for Alpha-Mannosidosis

New Research Explores Potential Treatment for Ataxia Telangiectasia
3 de December de 2024 | Medical News

New Research Explores Potential Treatment for Ataxia Telangiectasia

AI-Drug Discovery
3 de December de 2024 | Pharma Industry Insights

AI-Drug Discovery

Sustainability in the Pharmaceutical Industry: A Global Effort
3 de December de 2024 | Pharma Industry Insights

Sustainability in the Pharmaceutical Industry: A Global Effort

Pharma Mergers and Acquisitions on the Rise
3 de December de 2024 | Pharma Industry Insights

Pharma Mergers and Acquisitions on the Rise

Progress Towards Universal Health Coverage
3 de December de 2024 | Public Health

Progress Towards Universal Health Coverage

Measles on the rise in 2024
3 de December de 2024 | Public Health

Measles on the rise in 2024

1 2 Next »
iMedicines By Ingenima

Contact

  • Alejandra Saldaña
  • Science Park, Platinum Building Of. BC 19
  • Ruta 101 Km 23.500, 14000, Canelones
  • Uruguay
  • Tel: +598 2682 9862
  • asaldana@imedicinesgroup.com


  • TERMS OF USE – PRIVACY POLICY

Pharmacovigilance

We implement robust regional medical programs.

For further information on any product or activity, please reach out to our medical team at medicalinquiries@imedicinesgroup.com

Medical Inquiries

We run regional medical programs.

If you require additional information on any product or activity, please contact our medical team at medicalinquires@imedicinesgroup.com

Compliance

IMG is committed to long-term, sustainable growth, with clear and transparent ways of creating and delivering value to physicians and patients. We work hard every day to generate a positive impact for society.

IMG’s objectives are:
(i) Development and implementation of honest behaviors and control processes in accordance with international compliance standards.
(ii) Prevention and early detection of breaches of any law or regulation.

IMG encourages strict adherence to its Code of Conduct & Ethics. In our program, it is imperative to make ethical decisions in all aspects of business. As a service provider, we are committed to maintain the trust that IMG has earned from patients and other stakeholders. We are passionate about creating value for patients, patient safety, quality of our products, and our ethics and compliance. An independent team will develop proactive monitoring of business activities and processes which may provide opportunities for risk identification and early detection. This independent team of experts will continually develop online and in-person training and communications covering ethics and compliance-related risk areas. The main focus is:
(i) Healthcare compliance – interactions with healthcare professionals
(ii) Data privacy
(iii) Anti-bribery
(iv) Anti-corruption
(v) Transparency